Hudson Executive Capital LP Eagle Pharmaceuticals, Inc. Transaction History

Hudson Executive Capital LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2020 May 15, 2020	SELL	$34.37 - $60.07 $22.7 Million - $39.8 Million	-661,897 Closed	0 $0
Q4 2019 Feb 14, 2020	SELL	$54.32 - $64.31 $8.06 Million - $9.55 Million	-148,468 Reduced 18.32%	661,897 $39.8 Million
Q3 2019 Nov 14, 2019	SELL	$53.25 - $59.98 $75,189 - $84,691	-1,412 Reduced 0.17%	810,365 $45.8 Million
Q2 2019 Aug 14, 2019	SELL	$46.61 - $58.45 $7.42 Million - $9.31 Million	-159,223 Reduced 16.4%	811,777 $45.2 Million
Q3 2017 Nov 14, 2017	BUY	$46.62 - $60.36 $45.3 Million - $58.6 Million	971,000	971,000 $57.9 Million

8.6M

100

Ticker EGRX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 13,015,900
Market Cap $7.81M
Description
Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and in...

Get notified when there are updates to the investment portfolio of Hudson Executive Capital LP, based on Form 13F filings with the SEC.

Stay updated on Hudson Executive Capital LP with notifications on news.